Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults. (July 2015)

• Record Type: Journal Article
• Authors: Cox, Manon M. J.; Izikson, Ruvim; Post, Penny; Dunkle, Lisa
• Is Part Of: Therapeutic advances in vaccines. Volume 3:Number 4(2015:Oct.)
• Page Start: 97
• Page End: 108
• Publication Date: 2015-07
• Subjects: cell culture -- hemagglutinin -- immunogenicity -- influenza -- safety -- vaccine; Vaccines -- Periodicals; 615.372
• DOI: 10.1177/2051013615595595
• Languages: English
• ISSNs: 2051-0136

Abstract

Flublok is the first recombinant hemagglutinin (HA) vaccine licensed by the US Food and Drugs Administration for the prevention of influenza in adults aged 18 and older. The HA proteins produced in insect cell culture using the baculovirus expression system technology are exact analogues of wild type circulating influenza virus HAs. The universal HA manufacturing process that has been successfully scaled to the 21, 000L contributes to rapid delivery of a substantial number of doses. This review discusses the immunogenicity, efficacy and safety data from five pivotal clinical studies used to support licensure of trivalent Flublok for adults 18 years of age and older in the United States. The trial data demonstrate that the higher antigen content in Flublok results in improved immunogenicity. Data further suggest improved efficacy and a slightly lower local reactogenicity compared with standard inactivated influenza vaccine, despite the presence of more antigen (statistically significant). Flublok influenza vaccine can include HAs designed to mimic 'drift' in influenza viruses as the process of predicting antigenic drift advances and, at a minimum, could address late appearing influenza viruses. The implementation of the latter will require support from regulatory authorities.